Pharma Tech

Exegenesis Bio and Modalis sign research deal for Duchenne therapy

Sep 11, 2026, 10:28 AM

Read Full Article → Exegenesis Bio and Modalis sign research deal for Duchenne therapy

Translate article text

Choose a language and wait for the translated text.

Exegenesis Bio and Modalis Therapeutics have entered into a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for DMD.